Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2014

Open Access 01-06-2014 | Commentary

Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’

Author: Pierre Miossec

Published in: Arthritis Research & Therapy | Issue 3/2014

Login to get access

Excerpt

During the last 20 years, obvious progress has been made in the care of patients with rheumatoid arthritis (RA). This results from the combination of better diagnosis, earlier use of classic drugs, and the introduction of new targeted therapies. Despite these positive results, RA remains a chronic disease and induction of remission is still rarely obtained [1]. It is as if RA were a series of lost battles. More recently, although RA care improved, chronic inflammation was shown to have an effect on mortality, specifically from cardiovascular events. …
Literature
1.
Miossec P: Rheumatoid arthritis: still a chronic disease. Lancet. 2013, 381: 884-886. 10.1016/S0140-6736(12)62192-8.CrossRefPubMed
2.
3.
Emery P: Why is there persistent disease despite biologic therapy? Importance of early intervention. Arthritis Res Ther. 2014, 16: 115. 10.1186/ar4567.PubMedCentralCrossRefPubMed
4.
Kuca-Warnawin E, Burakowski T, Kurowska W, Prochorec-Sobieszek M, Radzikowska A, Chorazy-Massalska M, Maldyk P, Kontny E, Maslinski W: Elevated number of recently activated T cells in bone marrow of patients with rheumatoid arthritis: a role for interleukin 15?. Ann Rheum Dis. 2011, 70: 227-233. 10.1136/ard.2009.124966.CrossRefPubMed
5.
Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B: Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013, 381: 918-929. 10.1016/S0140-6736(12)61811-X.CrossRefPubMed
6.
Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO: Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008, 205: 2491-2497. 10.1084/jem.20072707.PubMedCentralCrossRefPubMed
7.
Marotte H, Maslinski W, Miossec P: Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005, 7: R149-R155. 10.1186/ar1465.PubMedCentralCrossRefPubMed
8.
Nistala K, Mauri C: Why is there persistent disease despite biological therapy? The quest for B cell targeted therapies in rheumatic disease. Arthritis Res Ther. 2014, 16: 116. 10.1186/ar4569.PubMedCentralCrossRefPubMed
9.
Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS: DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis. 2013, 72: 110-117. 10.1136/annrheumdis-2012-201526.PubMedCentralCrossRefPubMed
10.
Frank-Bertoncelj M, Gay S: The epigenome of synovial fibroblasts: an underestimated therapeutic target in RA. Arthritis Res Ther. 2014, 16: 117. 10.1186/ar4570.PubMedCentralCrossRefPubMed
11.
Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.PubMed
12.
Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR: Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013, 2: e01202. 10.7554/eLife.01202.PubMedCentralCrossRefPubMed
13.
Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, Alfredsson L: Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011, 70: 508-511. 10.1136/ard.2009.120899.PubMedCentralCrossRefPubMed
14.
Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY, Group for Respect of Ethics and Excellence in Science (GREES): Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011, 70: 1713-1718. 10.1136/ard.2011.154252.CrossRefPubMed
Metadata
Title
Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’
Author
Pierre Miossec
Publication date
01-06-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4592

Other articles of this Issue 3/2014

Arthritis Research & Therapy 3/2014 Go to the issue

Commentary

Why is there persistent disease despite biologic therapy? Importance of early intervention

Research article

Decreased interleukin 27 expression is associated with active uveitis in Behçet’s disease

Research article

Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis

Editorial

Goldilocks, vitamin D and sarcoidosis

Research article

B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren’s syndrome: the similarities and differences

Editorial

PEG-ing down (and preventing?) the cause of pegloticase failure
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits